Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 5/20 | 0.33 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | PRCP | P42785 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626472 | 1.00 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3KCNH2MAPT | |
| SCHEMBL19626342 | 0.90 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2MAPT | |
| SCHEMBL20840859 | 0.90 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2MAPT | |
| SCHEMBL21419017 | 0.80 | HTR2C (0.44) | KCNH2SLC6A9 | |
| SCHEMBL21419003 | 0.80 | HTR2C (0.44) | KCNH2SLC6A9 | |
| SCHEMBL19629604 | 0.80 | HTR2C (0.44) | KCNH2SLC6A9 | |
| SCHEMBL17725168 | 0.80 | HTR2C (0.44) | KCNH2SLC6A9 | |
| SCHEMBL17725308 | 0.80 | HTR2C (0.44) | KCNH2SLC6A9 | |
| SCHEMBL14135266 | 0.78 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3SLC6A9 | |
| SCHEMBL23466168 | 0.73 | LIG1 (0.42) | SLC6A2SLC6A4SLC6A3KCNH2SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | SLC6A2 106/4885SLC6A4 181/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.